Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross-sectional study from China.
Xiaowei Wei, Jie Zhao, Ping Zhu, Wenfang Niu, Zhangrong Xu, Xingwu Ran, Xiaomei Zhang, Aihong Wang, Linong Ji
{"title":"Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross-sectional study from China.","authors":"Xiaowei Wei, Jie Zhao, Ping Zhu, Wenfang Niu, Zhangrong Xu, Xingwu Ran, Xiaomei Zhang, Aihong Wang, Linong Ji","doi":"10.1111/dom.16514","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Lower extremity arterial disease (LEAD), a prevalent but under-recognised macrovascular complication of type 2 diabetes mellitus (T2DM), is closely linked to insulin resistance (IR). The estimated glucose disposal rate (eGDR), a surrogate marker of IR, may facilitate early LEAD risk stratification; however, its clinical utility remains underexplored.</p><p><strong>Materials and methods: </strong>This cross-sectional analysis of 7482 adults aged ≥50 years with T2DM, from the China DIA-LEAD study evaluated the association between eGDR (quartiles: Q1-Q4) and LEAD, defined by the ankle-brachial index (ABI <0.9 or >1.3). Multivariate logistic regression and restricted cubic spline (RCS) models were used to assess the nonlinear relationships, adjusted for demographics, metabolic factors and comorbidities.</p><p><strong>Results: </strong>Participants in the lower eGDR quartiles showed a progressively higher LEAD prevalence (Q1: 31.4% vs. Q4: 12.8%), worse glycaemic control (HbA1c Q1: 9.8% vs. Q4: 7.3%) and a greater comorbidity burden (all p < 0.001). In fully adjusted models, Q1 had a 2.23-fold higher LEAD risk versus Q4 (95% CI 1.47-3.37). Each 1-unit eGDR increase conferred a 24% lower LEAD risk (adjusted OR 0.76, 95% CI 0.70-0.84). RCS analysis revealed an L-shaped relationship, with sharp risk escalation at eGDR < 8 mg/kg/min (p for nonlinearity = 0.003). Subgroup analyses confirmed consistency across populations (all p for interaction >0.05).</p><p><strong>Conclusions: </strong>eGDR demonstrated a significant inverse L-shaped association with LEAD in patients with T2DM. These findings support the clinical utility of eGDR as a practical indicator of LEAD risk screening and management. Patients with lower eGDR may benefit from insulin-sensitising therapies, which could reduce both glucose levels and the risk of LEAD.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16514","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Lower extremity arterial disease (LEAD), a prevalent but under-recognised macrovascular complication of type 2 diabetes mellitus (T2DM), is closely linked to insulin resistance (IR). The estimated glucose disposal rate (eGDR), a surrogate marker of IR, may facilitate early LEAD risk stratification; however, its clinical utility remains underexplored.
Materials and methods: This cross-sectional analysis of 7482 adults aged ≥50 years with T2DM, from the China DIA-LEAD study evaluated the association between eGDR (quartiles: Q1-Q4) and LEAD, defined by the ankle-brachial index (ABI <0.9 or >1.3). Multivariate logistic regression and restricted cubic spline (RCS) models were used to assess the nonlinear relationships, adjusted for demographics, metabolic factors and comorbidities.
Results: Participants in the lower eGDR quartiles showed a progressively higher LEAD prevalence (Q1: 31.4% vs. Q4: 12.8%), worse glycaemic control (HbA1c Q1: 9.8% vs. Q4: 7.3%) and a greater comorbidity burden (all p < 0.001). In fully adjusted models, Q1 had a 2.23-fold higher LEAD risk versus Q4 (95% CI 1.47-3.37). Each 1-unit eGDR increase conferred a 24% lower LEAD risk (adjusted OR 0.76, 95% CI 0.70-0.84). RCS analysis revealed an L-shaped relationship, with sharp risk escalation at eGDR < 8 mg/kg/min (p for nonlinearity = 0.003). Subgroup analyses confirmed consistency across populations (all p for interaction >0.05).
Conclusions: eGDR demonstrated a significant inverse L-shaped association with LEAD in patients with T2DM. These findings support the clinical utility of eGDR as a practical indicator of LEAD risk screening and management. Patients with lower eGDR may benefit from insulin-sensitising therapies, which could reduce both glucose levels and the risk of LEAD.
期刊介绍:
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.